Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gastrointestinal stromal tumors.

Margaret von Mehren1, James C Watson

  • 1Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. Margaret.vonMehren@fccc.edu

Hematology/Oncology Clinics of North America
|June 9, 2005
PubMed
Summary

Gastrointestinal stromal tumors (GISTs) are managed with imatinib, a targeted therapy. This review covers current GIST treatments and emerging therapies for imatinib-resistant cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Management of multifocal and metastatic retroperitoneal sarcoma: an updated consensus approach from the transatlantic australasian retroperitoneal sarcoma working group (TARPSWG).

Cancer treatment reviews·2026
Same author

Addendum: Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial.

Nature communications·2025
Same author

DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas.

Cancers·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastroenterology

Background:

  • Gastrointestinal stromal tumors (GISTs) are primarily diagnosed by KIT expression.
  • Imatinib mesylate, a tyrosine kinase inhibitor, has revolutionized GIST management.
  • Understanding GIST molecular pathways is crucial for effective treatment.

Purpose of the Study:

  • To review the current management of GISTs.
  • To discuss the role of imatinib in adjuvant and metastatic settings.
  • To explore novel therapies for imatinib-resistant GISTs.

Main Methods:

  • Literature review of GIST management strategies.
  • Analysis of surgical and imatinib-based treatment protocols.
  • Examination of emerging therapeutic targets and agents.

Main Results:

  • Imatinib has significantly altered the treatment landscape for GISTs.
  • Surgery remains a key component, often combined with imatinib.
  • Imatinib resistance presents a growing clinical challenge.

Conclusions:

  • Current GIST management integrates molecular therapies, primarily imatinib.
  • Adjuvant and metastatic GIST treatment requires tailored approaches.
  • Development of novel therapies is essential to overcome imatinib resistance.

Related Experiment Videos